NCT02805777

Brief Summary

As continuous positive airway pressure is the treatment choice for OSA, a mask is vital in ensuring the effectiveness of therapy delivery. The study will evaluate the performance of a new mask system with diffuse vent technology. This is done by characterizing the mask flow over time and compare the performance between patients who apply 2 different washing procedures to the mask. The study will also subjectively assess breathing comfort and performance of the mask system.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started May 2017

Shorter than P25 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 1, 2016

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 20, 2016

Completed
11 months until next milestone

Study Start

First participant enrolled

May 1, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

February 4, 2021

Status Verified

February 1, 2021

Enrollment Period

7 months

First QC Date

June 1, 2016

Last Update Submit

February 2, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in vent flow of the mask system, which will be recorded on a flow testing rig (units= LPM). Baseline flow in LPM will be compared to that at the conclusion of the trial.

    The mask system will be flow tested after use when returned by the participant at each scheduled visit. The flow of the mask system will be recorded as per the mask to flow procedure of ISO17510 Sleep apnoea breathing therapy - Part 2: Annex B Exhaust flow test procedure. The results will be reported as an average flow in LPM. Results will be presented graphically with average flow on the vertical axis and use time (weeks) on the horizontal axis. This will allow us to assess any changes in vent flow over time.

    12 weeks

Secondary Outcomes (3)

  • Parameters such as the apnoea/hypopnoea index (AHI) will be recorded and analysed

    12 weeks

  • Questionnaire to assess the perceived overall performance of the mask by the participant. Questions around comfort will be asked.

    12 weeks

  • Bioburden quantification by laboratory testing of venting components at end of trial

    12 weeks

Study Arms (2)

Washing procedure 1

EXPERIMENTAL

this group will apply washing technique 1

Device: CPAP mask

Washing procedure 2

EXPERIMENTAL

this group will apply washing technique 2

Device: CPAP mask

Interventions

CPAP maskDEVICE

A new vent CPAP mask system will be used in this trial

Washing procedure 1Washing procedure 2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants willing to give written informed consent
  • Participants who can read and comprehend English
  • Participants using APAP for \>6 months
  • Participants who are willing to use the mask system for the 3 month duration of the trial.
  • Participants who are over 18 years of age
  • Participants who currently use a nasal mask system

You may not qualify if:

  • Participants not willing to give written informed consent
  • Participants who cannot read and comprehend English
  • Participants using an inappropriate mask system
  • Participants on a Bilevel or ASV therapy
  • Participants who are pregnant
  • Participants with a pre-existing lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer lung injury; fibrosis of the lungs; recent (\< 2years) case of pneumonia or lung infection
  • Participants or whose bed partner with implantable metallic implants in the head, neck and chest region affected by magmetic fields (Non-ferrous implants may be acceptable)
  • Participants that weight \<30 kg
  • Participants who are unsuitable to participate in the study in the opinion of the researcher

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Klaus Schindhelm, PhD

    ResMed/The University of New South Wales

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2016

First Posted

June 20, 2016

Study Start

May 1, 2017

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

February 4, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

There is no sharing plan.